Safeguarding Public Health in Medicine

AMA Sunbeam

The Sunbeam deal did indeed raise questions about the credibility of the American Medical Association (AMA). Critics argued that the AMA\\\\\\\'s endorsement of Sunbeam products could create a conflict of interest, potentially compromising the association\\\\\\\'s ability to objectively evaluate Sunbeam products in the future.

For instance, Michael Jacobson, executive director of the Center for Science in the Public Interest, a consumer advocacy group, stated: \\\\\\\"It immediately sets up a conflict of interest. In the future, how can the AMA evaluate any Sunbeam product and warn the public if they are defective? Or what if they are good products, but twice as expensive as those made by other companies?\\\\\\\" (Nanda, 2002, p. 11).

Moreover, Mildred Cho, a professor at the University of Pennsylvania Center for Bioethics, argued that the AMA was violating its own policies by accepting royalty payments from Sunbeam in exchange for endorsing its products. She referred to two AMA policies: \\\\\\\"Under no circumstances may physicians place their own financial interests above the welfare of their patients\\\\\\\" and \\\\\\\"A physician should not be influenced in the prescribing of drugs, devices, or appliances by a direct or indirect financial interest in a pharmaceutical firm or other supplier\\\\\\\" (Nanda, 2002, p. 11).